Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2015–2018

INTEGRATE · Interdisciplinary Training Network for Validation of Gram-Negative Antibacterial Targets

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-01-01 → 2018-12-31
Финансиране от ЕС
2 793 331 €
Участници
14
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Нови мишени и вещества за борба с грамотрицателните бактерии се търсят чрез идентифициране на нови химични структури и методи за тяхното действие. Това помага за разработването на ефективни антимикробни средства срещу бактерии, които са станали устойчиви на много лекарства.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Interdisciplinary Training Network for Validation of Gram-Negative Antibacterial Targets

Antimicrobial resistance is posing a continuously-rising threat to global health. One key recommendation from the recent “Action plan against the rising threats from Antimicrobial Resistance” report (the Commission to the European Parliament and Council (15.11.2011)) is the development of effective antimicrobials or alternatives for treatment of human and animal infections. The INTEGRATE project is a direct response to this. We have assembled a team of ten beneficiaries from eight EU member states, encompassing both academic and nonacademic sectors and different disciplines, to form a consortium committed to train Early Stage Researchers (ESRs) in the discovery and preclinical validation of novel Gram-negative antibacterial targets and agents. The principal objective of the consortium was to provide a training platform where students are exposed to every aspect of the antimicrobial discovery process, ranging from target identification and validation, through organic synthesis, in silico design and compound screening, to mode-of-action and possible resistance mechanisms. This exposure was supported by a concrete secondment plan, coupled with a series of high-level consortium-wide training events and networking programs. The INTEGRATE project foresaw four main scientific objectives to tackle down multidrug resistant bacteria: 1) identifying and optimizing novel chemotypes; 2) establishing new tools and resources for antibacterial drug discovery; 3) validating non-canonical targets for combating Gram-negative bacterial infections; 4) strengthening inter-sectorial and multidisciplinary collaborations towards discovery of new antibacterial agents. Through this, INTEGRATE contributed to overcoming the fragmentation of approaches that often characterize drug discovery and trained 11 ESRs in a multi-disciplinary environment. The training-through-research part of INTEGRATE focused on several gram-negative targets, not yet exploited clinically, for which we intended to clarify their potential relevance in the bacterial fitness, and for which we intended to progress a series of small-molecules lead candidates for further development. The training-through-research plan is flanked by an active program of soft-skill acquisition and by a dissemination plan to increase the general awareness on the importance of basic research to fight bacterial infections

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Antimicrobial resistance is posing a continuously-rising threat to global health. Indeed, one key recommendation from the recent “Action plan against the rising threats from Antimicrobial Resistance” report (submitted by the Commission to the European Parliament and Council (15.11.2011)) is the development of effective antimicrobials or alternatives for treatment of human and animal infections. The INTEGRATE project is a direct response to this. We have assembled a team of 10 beneficiaries from eight EU member states, encompassing both academic and non-academic sectors and different disciplines, to form a consortium committed to training Early Stage Researchers (ESRs) in the discovery and preclinical validation of novel Gram-negative antibacterial agents and antibacterial targets. The principle aim of the consortium is to provide a training platform where students are exposed to every aspect of the antimicrobial discovery process, ranging from target identification and validation, through organic synthesis, in silico design and compound screening, to mode-of-action and possible resistance mechanisms. This exposure will be accomplished through a concrete secondment plan, coupled with a series of high-level consortium-wide training events and networking programmes. Our intention is to reverse the current fragmentation of approaches towards antibacterial discovery through mutual cooperation. The INTEGRATE training framework is built on an innovative research project aimed at targeting important but non-essential gene products as an effective means of reducing bacterial fitness, thereby facilitating clearance of the pathogen by the host immune system. To achieve this, the individual work programmes have been designed to seamlessly inter-mesh contributions from the fields of in silico design, organic synthesis, molecular biology and biochemistry, and the very latest in vitro and in vivo screening technologies.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз